Biomedical Engineering Reference
In-Depth Information
at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm070968.pdf. Accessed October 2002.
26. HIVSurrogateMarker Collaborative, Group. Human immunodeficiency virus type 1 RNA
level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV
Surrogate Marker Collaborative Group. AIDS Res. Hum. Retroviruses 2000;16:
1123-1133.
27. Moss AR, Bacchetti P. Natural history of HIV infection. AIDS 1989;3(2):55-61.
28. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, BattegayM, Vernazza P,
Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A. AIDS-related
opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss
HIV Cohort Study. JAMA 1999;282(23):2220-2226.
29. StiehmER, editor. Immunologic Disorders in Infants and Children, 4th ed.,W.B. Saunders
Company, Philadelphia, PA, 1996, p.217.
30. Denny T. et al. Lymphocyte subsets in healthy children during the first 5 years of life. JAMA
1992;267:1484-1488.
31. U.S., Public Health Service and the Infectious Diseases Society of, America. Criteria for
starting, discontinuing, and restarting opportunistic infection prophylaxis for adults with
human immunodeficiency virus infection, 2002.
32. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H, Centers for Disease
Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association
of the Infectious Diseases Society of America. Guidelines for prevention and treatment of
opportunistic infections in HIV-infected adults and adolescents: recommendations from
CDC, theNational Institutes of Health, and the HIVMedicine Association of the Infectious
Diseases Society of America. MMWR Recomm. Rep. 2009;58(RR-4):1-207.
33. Panel on Antiretroviral Guidelines for Adults and, Adolescents. Guidelines for the use of
antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and
Human Services, November 3, 2008, pp.1-139. Available at http://www.aidsinfo.nih.gov/
ContentFiles/AdultandAdolescentGL.pdf. Accessed Jun. 16, 2008, p. 7, Table 5a.
34. Phillips AN, Lee CA, Elford J, Janossy G, Kernoff PB. The cumulative risk of AIDS as the
CD4 lymphocyte count declines. JAIDS 1992;5:148-152.
35. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability
in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-
infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J.
Acquir. Immune. Defic. Syndr. 1990;3(2):144-151.
36. Dyrhol-Riise AM, Voltersvik P, Rosok BI, Olofsson J, Asjo B. Normalization of CD4
þ
cell numbers and reduced levels of memory CD8
þ
cells in blood and tonsillar tissue after
highly active antiretroviral therapy in early HIV type-1 infection. AIDS Res. Hum.
Retroviruses 2000;16:191-201.
37. Antiretroviral Therapy Cohort, Collaboration. Importance of baseline prognostic factors
with increasing time since initiation of highly active antiretroviral therapy: collaborative
analysis of cohorts of HIV-1-infected patients. J. Acquir. Immune. Defic. Syndr.
2007;46:607-615.
38. Uy J, Armon C, Buchacz K, Wood K, Brooks JT; the HOPS Investigators. Initiation of
HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral
drug resistance mutations at virologic failure. J. Acquir. Immune. Defic. Syndr. 2009;51
(4):450-453.
Search WWH ::
Custom Search